血必净联合前列地尔治疗脑梗死急性期的疗效及安全性观察

Effect and safety of Xuebijing combined Alprostadil in the treatment of acute period of cerebral infarction

目的观察血必净联合前列地尔治疗脑梗死急性期的疗效与安全性。方法 70例脑梗死急性期患者进行分组治疗,观察组给予血必净联合前列地尔,对照组给予前列地尔。观察2组有效率、美国国立卫生院神经功能缺损评分(NIHSS)以及肝、肾功能等指标。结果观察组有效率94.29%,高于对照组的77.14%,差异有统计学意义(P<0.05)。治疗前2组NIHSS评分差异无统计学意义(P>0.05),治疗后7、14、21d,观察组NIHSS评分均显著低于对照组,差异有统计学意义(P<0.05)。2组肝、肾功能等方面差异均无统计学意义(P>0.05)。结论血必净联合前列地尔治疗脑梗死急性期,具有较好的临床疗效,能够一定程度上恢复患者的神经功能,安全可靠,值得推广。

Objective To observe the clinical effect and safety of Xuebijing combined Alprostadil in the treatment of acute period of cerebral infarction. Methods Seventy patients with acute period of cerebral infarction were divided into 2 groups. Observation group was given Xuebijing combined Alprostadil, while control group was given Alprostadil only. The effective rate, NIHSS score and safety index of liver and kidney function of the two groups were compared. Results The effective rate of observation group was higher than control group（P〈0.05）. No statistical difference existed on NIHSS scores between the two groups, but at 7, 14 and 21d after treatment, NIHSS score of observation group was obviously lower than control group, P〈 0.05. Besides, on safety index of liver and kidney functions, no statistical difference existed between the two groups, P〉0.05. Conclusion Xuebijing combined Alprostadil for treatment of acute period of cerebral infarction has a high clinical effec- tive rate, it can promote recovery of nerve function of patients to some extent and it is safe and reliable, so it is worth of being popularized.